Treatment of hepatitis C virus genotype 3-infection

Liver International

Volumn 34, Issue SUPPL1, 2014, Pages 18-23

  Pol, Stanislas ^a   Vallet Pichard, Anaïs ^a   Corouge, Marion ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Cirrhosis; Combination therapy; Direct acting antiviral; Hepatitis C virus; Polymerase inhibitor; Protease inhibitor; Replication complex inhibitor

Indexed keywords

ABT 072; ABT 267; ABT 333; ABT 450; ALISPORIVIR; ANTIVIRUS AGENT; ASUNAPREVIR; BI 207127; BMS 791325; BOCEPREVIR; CYCLOPHILIN; DACLATASVIR; DANOPREVIR; FILIBUVIR; IDX 184; LEDIPASVIR; LOMIBUVIR; MERICITABINE; MK 5172; PEGINTERFERON ALPHA; PPI 668; RIBAVIRIN; RITONAVIR; SCY 635; SETROBUVIR; SIMEPREVIR; SOFOSBUVIR; TEGOBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; DRUG POTENCY; DRUG TOLERANCE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; IN VITRO STUDY; LIVER CIRRHOSIS; MONOTHERAPY; PATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS REPLICATION;

CIRRHOSIS; COMBINATION THERAPY; DIRECT-ACTING ANTIVIRAL; HEPATITIS C VIRUS; POLYMERASE INHIBITOR; PROTEASE INHIBITOR; REPLICATION COMPLEX INHIBITOR;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMIDAZOLES; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; STANDARD OF CARE; TIME FACTORS; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE; VIRAL NONSTRUCTURAL PROTEINS; VIRAL PROTEINS;

EID: 84890868782     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12405     Document Type: Review

References (39)

1. Coppola N, Vatiero LM, Sagnelli E. HCV genotype 2 as a risk factor for reactivation of chronic HCV infection. Gut 2005; 54: 1207.
2. Nkontchou G, Ziol M, Aout M, et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepatol 2011; 18: e516-22.
3. Larsen C, Bousquet V, Delarocque-Astagneau E, et al. Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France. J Med Virol 2010; 82: 1647-54.
4. Bochud PY, Cai T, Overbeck K, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009; 51: 655-66.
5. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
6. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
7. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
8. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 993-9.
9. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis C virus infection. J Hepatol 2011; 55: 245-64.
10. Andriulli A, Mangia A, Iacobellis A, et al. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther 2008; 28: 397-404.
11. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 453-63.
12. Buhler S, Bartenschlager R. New targets for antiviral therapy of chronic hepatitis C. Liver Int 2012; 32(Suppl.): 9-16.
13. Donnelly RP, Kotenko SV. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res 2010; 30: 555-64.
14. Flisiak R, Dumont JM, Crabbe R. Cyclophilin inhibitors in hepatitis C viral infection. Expert Opin Investig Drugs 2007; 16: 1345-54.
15. Jacobson IM, Brown RS, Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007; 46: 971-81.
16. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
17. Shiffman ML, Suter F, Bacon BR, et al. Peg-interferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124-34.
18. Di Martino V, Richou C, Cervoni JP, et al. Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled, trials and implications for the future. Hepatology 2011; 54: 789-800.
19. Cheinquer H, Shiffman ML, Zeuzem S, et al. The outcome of 24 vs 48 weeks of peginterferon alfa-2a (40KD) plus ribavirin on sustained virologic response rates in patients infected with genotype 2 or 3 hepatitis C virus who do not achieve a rapid viral response: the N-CORE study. Hepatology 2013; 56(Suppl. 1): 271A.
20. Foster GR, Hezode C, Bronowicki JP, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011; 141: 881-9.
21. Lenz O, Vijgen L, Berke JM, et al. Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202). J Hepatol 2013; 58: 445-51.
22. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465: 96-100.
23. Pol S, Ghalib RH, Rustgi VK, et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis 2012; 12: 671-7.
24. Dore GJ, Lawitz E, Hezode C, et al. Daclatasvir combined with peginterferon alfa-2a and ribavirin for 12 or 16 weeks in patients with hepatitis C virus genotype 2 or 3 infection: COMMAND GT 2/3 study. J Hepatol 2012; 58(Suppl. 1): S570-1.
25. Pockros P, Jensen D, Tsai N, et al. SVR-12 among G1/4 treatment-naive patients receiving Mericitabine in combination with PEG-IFN a-2A/RBV: interim analysis from the JUMP-C study. J Hepatol 2012; 56(Suppl. 2): S477-8.
26. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor Sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44.
27. Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naïve patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13: 401-08.
28. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216-24.
29. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Eng J Med 2013; 368: 1878-87.
30. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77.
31. Gane E, Lawitz E, Rodriguez-Torres M, et al. Phase 3 randomized controlled trial of all oral treatment with Sofosbuvir + ribavirin for 12 weeks compared to 24 weeks of Peg + ribavirin in treatment-naïve GT 2/3 HCV-infected patients (FISSION). J Hepatol 2013; 58(Suppl. 1): S3.
32. Nelson DR, Feld J, Kowdley KV, et al. All oral therapy with Sofosbuvir + ribavirin for 12 or 16 weeks in treatment experienced GT 2/3 HCV-infected patients: results of the phase 3 FUSION trial. J Hepatol 2013; 58(Suppl. 1): S3-4.
33. th Conference on Retroviruses and Opportunistic Infections (CROI 2013). Atlanta, March 3-6 2013. Abstract 155LB.
34. Lawitz E, Poordad F, Pang P, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2013; doi: 10.1016/S0140-6736(13)62121-2 [Epub ahead of print].
35. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Sustained virologic response with Daclatasvir plus Sofosbuvir +/- ribavirin (RBV) in chronic HCV genotype (GT) 1 -infected patients who previously failed Telaprevir (TVR) or Boceprevir (BOC). J Hepatol 2013; 58(Suppl. 1): S570.
36. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. High rate of sustained virologic response with the all-oral Combination of Daclatasvir (NS5A inhibitor) plus Sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naïve patients chronically infected with HCV genotype 1, 2, or 3. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012). Boston, November 9-13, 2012. Abstract LB-02.
37. Kowdley KV, Lawitz E, Poordad F, et al. A 12-week interferon-free treatment regimen with ABT 450/r, ABT-267, ABT-333, and ribavirin achieves SVR12 rates (observed data) of 99% in treatment naïve patients and 93% in prior null responders in HCV genotype 1 infection. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012). Boston, November 9-13, 2012. Abstract LB-01.
38. Everson GT, Sims KD, Rodriguez-Torres M, et al. An Interferon-free, Ribavirin-free 12-Week Regimen of Daclatasvir (DCV), Asunaprevir (ASV), and BMS-791325 Yielded SVR4 of 94% in Treatment-Naive Patients with Genotype (GT) 1 Chronic Hepatitis C Virus (HCV) Infection. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012). Boston, November 9-13, 2012. Abstract LB-3.
39. Pawlotsky JM, Sarin SK, Foster G, et al. Alisporivir plus ribavirin is highly effective as interferon-free or interferon-add-on regimen in previously untreated HCV-GT2 or GT3 patients: SVR12 results from VITAL-1 phase 2b study. J Hepatol 2012; 56(Suppl. 2): S553.